Quest PharmaTech Inc. announced the re-election of 4 directors to its Board of Directors at the annual general meeting of shareholders. Shareholders also reappointed the Company’s auditors, Kingston Ross Pasnak, LLP. Approximately 50,288,000 shares were voted, representing 29.7% of eligible shares. The Company also granted 1,900,000 stock options to Directors and Officers at $0.05 per common share. Quest PharmaTech is focused on developing products to improve the quality of life through investee companies and proprietary technologies, with a particular focus on cancer theranostic agents.

Read more at GlobeNewswire: Quest PharmaTech Announces Results from AGM